1039 ET - Gilead Sciences are weaker following news the Health and Human Services Department is considering cutting funding for HIV prevention, but analysts believe that threat poses only moderate risk. Potential cuts to CDC funding would not limit access to pre-exposure prophylaxis, a preventative treatment for HIV patients, because the organization only works on research, not providing the drugs, JPMorgan analysts say. The Centers for Disease Control and Prevention, which is part of HHS, spent about $1.3 billion in HIV funding as of 2023, BMO analyst Evan David Seigerman says, the removal of which "should only represent a modest headwind" to Gilead. Gilead is off 3.7%. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
March 19, 2025 10:39 ET (14:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。